ArticleCirculation2008
Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries.
Article in Circulation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 74 citations in OpenAlex.
- Cardiac Repair and Regeneration via Advanced Technology: Narrative Literature Review.JMIR biomedical engineering · 2025Review
- Article
- Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptide.Atherosclerosis · 2024Article
- Intraprocedural endothelial cell seeding of arterial stents via biotin/avidin targeting mitigates in-stent restenosis.Scientific reports · 2022Article
- Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.Scientific reports · 2022Article
- Stent-Based Gene Delivery for Coronary Disease.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Adeno-Associated Viral Vector Immobilization and Local Delivery from Bare Metal Surfaces.Methods in molecular biology (Clifton, N.J.) · 2022Article
- miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis.Bioactive materials · 2021Article
- Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization.Journal of visualized experiments : JoVE · 2020Article
- Stability and bioactivity of pepCD47 attachment on stainless steel surfaces.Acta biomaterialia · 2020Article
- PEGylated Polyethylenimine Derivative-Mediated Local Delivery of the shSmad3 Inhibits Intimal Thickening after Vascular Injury.BioMed research international · 2019Article
- Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis.Gene therapy · 2017Article
- Enhanced biocompatibility of CD47-functionalized vascular stents.Biomaterials · 2016Article
- Nanotechnology in diagnosis and treatment of coronary artery disease.Nanomedicine (London, England) · 2016Review
- Novel A20-gene-eluting stent inhibits carotid artery restenosis in a porcine model.Drug design, development and therapy · 2016Article
- Functional behavior and gene expression of magnetic nanoparticle-loaded primary endothelial cells for targeting vascular stents.Nanomedicine (London, England) · 2015Article
- Vascular gene transfer from metallic stent surfaces using adenoviral vectors tethered through hydrolysable cross-linkers.Journal of visualized experiments : JoVE · 2014Article
- A CARD9 polymorphism is associated with decreased likelihood of persistent conjugated hyperbilirubinemia in intestinal failure.PloS one · 2014Article
- Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis.Theranostics · 2014Review
- Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction.Biomaterials · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundLocal drug delivery from polymer-coated stents has demonstrated efficacy for preventing in-stent restenosis; however, both the inflammatory effects of polymer coatings and concerns about late outcomes of drug-eluting stent use indicate the need to investigate innovative approaches, such as combining localized gene therapy with stent angioplasty. Thus, we investigated the hypothesis that adenoviral vectors (Ad) could be delivered from the bare-metal surfaces of stents with a synthetic complex for reversible vector binding. METHODS AND
resultsWe synthesized the 3 components of a gene vector binding complex: (1) A polyallylamine bisphosphonate with latent thiol groups (PABT), (2) a polyethyleneimine (PEI) with pyridyldithio groups for amplification of attachment sites [PEI(PDT)], and (3) a bifunctional (amine- and thiol-reactive) cross-linker with a labile ester bond (HL). HL-modified Ad attached to PABT/PEI(PDT)-treated steel surfaces demonstrated both sustained release in vitro over 30 days and localized green fluorescent protein expression in rat arterial smooth muscle cell cultures, which were not sensitive to either inhibition by neutralizing anti-Ad antibodies or inactivation after storage at 37 degrees C. In rat carotid studies, deployment of steel stents configured with PABT/PEI(PDT)/HL-tethered adenoviral vectors demonstrated both site-specific arterial Ad(GFP) expression and adenovirus-luciferase transgene activity per optical imaging. Rat carotid stent delivery of adenovirus encoding inducible nitric oxide synthase resulted in significant inhibition of restenosis.
conclusionsReversible immobilization of adenovirus vectors on the bare-metal surfaces of endovascular stents via a synthetic complex represents an efficient, tunable method for sustained release of gene vectors to the vasculature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.